The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.